ARTICLE | Clinical News
Genmab's Arzerra misses in Phase III for indolent NHL
May 24, 2018 6:32 PM UTC
Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III COMPLEMENT A+B trial to treat indolent B cell non-Hodgkin's lymphoma. The company said full data from the trial will be submitted for publication at a medical meeting.
The open-label COMPLEMENT A+B trial enrolled 346 patients with indolent B cell NHL who were unresponsive to Rituxan rituximab or a Rituxan-containing regimen to receive up to eight cycles of Treanda in combination with 12 doses of Arzerra, or Treanda alone...
BCIQ Target Profiles